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Abstract 
Androgens are the obligatory precursors of estrogens. In humans, classic androgen 
biosynthesis yields testosterone, thought to represent the predominant circulating 
active androgen both in men and women. However, recent work has shown that 
11-ketotestosterone, derived from the newly described 11-oxygenated androgen bio-
synthesis pathway, makes a substantial contribution to the active androgen pool in 
women. Considering that classic androgens are the obligatory substrates for estrogen 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, 
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biosynthesis catalyzed by cytochrome P450 aromatase, we hypothesized that 11-oxygen-
ated androgens are aromatizable. Here we use steroid analysis by tandem mass spec-
trometry to demonstrate that human aromatase generates 11-oxygenated estrogens 
from 11-oxygenated androgens in 3 different cell-based aromatase expression sys-
tems and in human ex vivo placenta explant cultures. We also show that 11-oxygen-
ated estrogens are generated as a byproduct of the aromatization of classic androgens. 
We show that 11β-hydroxy-17β-estradiol binds and activates estrogen receptors α and β 
and that 11β-hydroxy-17β-estradiol and the classic androgen pathway-derived active es-
trogen, 17β-estradiol, are equipotent in stimulating breast cancer cell line proliferation 
and expression of estrogen-responsive genes. 11-oxygenated estrogens were, however, 
not detectable in serum from individuals with high aromatase levels (pregnant women) 
and elevated 11-oxygenated androgen levels (patients with congenital adrenal hyper-
plasia or adrenocortical carcinoma). Our data show that while 11-oxygenated androgens 
are aromatizable in vitro and ex vivo, the resulting 11-oxygenated estrogens are not de-
tectable in circulation, suggesting that 11-oxygenated androgens function primarily as 
androgens in vivo.
Key Words: 11-oxygenated androgens, 11-oxygenated estrogens, cytochrome P450 aromatase, 11-ketotestosterone, 
11-ketoestradiol, 11-ketoestrone
In humans, androstenedione (A4) is the immediate sub-
strate for testosterone biosynthesis. Testosterone (T) and 
its 5α-reduced form, 5α-dihydrotestosterone (DHT), 
are potent human androgens that bind and activate the 
human androgen receptor (AR). In the human adrenal, 
A4 is also converted to 11β-hydroxyandrostenedione 
(11OHA4), previously thought to be an inactive, 
dead-end metabolite. However, recent studies have shown 
that this abundant adrenal steroid serves as the key pre-
cursor for the newly described 11-oxygenated androgen 
biosynthesis pathway, through consecutive conversion to 
11-ketoandrostenedione (11KA4) and 11-ketotestosterone 
(11KT) (1-5). 11KT is a potent androgen that binds and 
activates the AR with similar affinity, potency, and efficacy 
to T (1, 6). Subsequent studies have shown that 11KT 
circulates at similar or higher levels than T in healthy 
women and represents the predominant circulating an-
drogen in androgen-excess conditions such as polycystic 
ovary syndrome and congenital adrenal hyperplasia (7-
10). Moreover, unlike classic androgens, circulating levels 
of 11-oxygenated androgens appear not to decline after 
menopause (8, 11).
T serves as a precursor to the potent estrogen 
17β-estradiol (E
2), while A4 can be converted to the weaker 
estrogen estrone (E1). Since androgens are obligatory pre-
cursors to estrogen biosynthesis catalyzed by the enzyme 
cytochrome P450 aromatase (CYP19A1), it appears emi-
nently plausible that 11-oxygenated androgens could also 
serve as substrates for aromatase, potentially yielding a 
novel class of active, 11-oxygenated estrogens. Here we 
comprehensively investigated the biosynthesis and estro-
genic activity of 11-oxygenated estrogens.
Materials and Methods
Cell lines
HEK293, COS-1, and JEG3 cells were purchased from the 
American Type Culture Collective. MCF7 cells were pur-
chased from the European Collection of Authenticated Cell 
Cultures, and MCF7-BUS cells were a gift from A.  Soto. 
HEK293 and MCF7-BUS cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 
10% fetal bovine serum (FBS) (heat-inactivated for 
MCF7-BUS cells) and 1% penicillin-streptomycin, while 
JEG3, MCF7, and MCF7arom were maintained in Eagle’s 
Minimum Essential Medium supplemented with 10% FBS 
and 1% penicillin-streptomycin. MCF7arom cells were de-
veloped and maintained as previously described (12). Cell 
lines were authenticated by short-tandem repeat profiling 
(NorthGene) and were regularly tested for mycoplasma 
contamination.
Plasmid constructs
The pcDNA4/17β-hydroxysteroid dehydrogenase type 
2 (HSD17B2) and pcDNA4/HSD17B4 plasmids were 
gifts from J.  Adamski. The pCR3/11β-hydroxysteroid 
dehydrogenase type 2 (HSD11B2) plasmid was a gift 
from P.M. Stewart. W.L. Miller provided the pCMV/
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and pCMV/CYP11B2 plasmids, and the pCIneo/ADX 
plasmid were from R.C. Tuckey. The pcDNA3.1/
aromatase plasmid was purchased from Genscript 
Biotech. The pSG5/hERα and pSG5/hERβ plasmid 
vectors were from F.  Gannon, and the pGL3-2xERE-





3,11β,17β-triol; 11OHE2), 11β-hydroxytestosterone 
(4-androsten-11β,17β-diol-3-one; 11OHT), 11-ketoand-
rostenedione (4-androsten-3,11-17-trione; 11KA4), 
11-ketotestosterone (4-androsten-17β-ol-3,11-dione; 11KT), 
androstenedione (4-androsten-3,17-dione; A4) and T 
(4-androsten-17β-ol-3-one; T) were purchased from 
Steraloids. 17β-Estradiol (1,3,5(10)-estratrien-3, 17β-diol; 
E2), bisphenol A  (4,4′-(propane-2,2,diyl)diphenol; BPA), es-
trone (1,3,5(10)-estratien-3-ol-17-one; E1), fulvestrant (ICI), 
and letrozole were purchased from Sigma-Aldrich, and 
11β-hydroxyandrostenedione 2,2,4,6,6,16,16-D7 (D7- 
11OHA4) and T 1,2-D2 (D2-T) were from Cambridge 
Isotopes. [2,4,6,7-3H(N)]-estradiol ([3H]-E2) and [1β-
3H(N)]-
androst-4-ene-3,17-dione ([3H]-A4) were from PerkinElmer 
Life.
Steroid conversion by CypExpress Aromatase
Aromatase conversion by the CypExpress Aromatase eu-
karyotic system (Oxford Biomedical Research) was carried 
out according to the manufacturer’s protocol. Each reac-
tion contained 20-mg CypExpress powder, 5-mM glucose-
6-phosphate, 2-mM oxidized nicotinamide adenine 
dinucleotide phosphate (NADP+) (Roche Diagnostics), and 
1-µM steroid substrate (with or without 10-µM letrozole) 
in 1-mL 100  mM potassium phosphate buffer (pH 7.4). 
Reactions were incubated at 37 °C for 4 hours with con-
tinuous stirring.
Aromatase assays in aromatase-expressing 
cell lines
Aromatase activity in the MCF7, MCF7arom, and JEG3 
cells were compared using a tritiated water assay as pre-
viously reported (12). Subsequently the MCF7arom and 
JEG3 cells were treated with 1  µM of the appropriate 
steroid (A4, T, 11OHA4, 11OHT, 11KA4, 11KT with 
and without 10-µM letrozole) for 24 hours. The protein 
concentration of the cell lysate was determined using a 
Pierce BCA kit (Thermo Fisher Scientific).
Enzyme assays in transiently transfected 
HEK293 cells
CYP11B1 and CYP11B2 enzyme assays were performed 
in transiently transfected HEK293 cells as previously de-
scribed (13).
Steroid conversion in placenta tissue
Fresh human placental tissue was obtained from healthy 
pregnant women undergoing elective cesarean delivery 
at term (37-40 weeks’ gestational age; as determined 
by ultrasound measurement of crown rump length) 
at the Birmingham Women’s Hospital, Birmingham 
Women’s & Children’s Hospital Foundation Trust, 
Birmingham, UK. All participating women provided written 
informed consent prior to tissue collection (13/WM/0178 
[2013]). Placental samples were identified macroscopic-
ally under sterile conditions and washed thoroughly with 
phosphate-buffered saline. Full-thickness, whole-tissue 
biopsies (decidual and trophoblast) (500-1000  mg) were 
dissected, washed in phosphate-buffered saline, and dis-
sected into 4 to 6 pieces and added to 5 mL phenol-red free 
DMEM/F12 media containing 1% penicillin-streptomycin 
and 1-µM steroid substrate. Placental explants were incu-
bated for 40 hours at 37 °C in a hybridizing oven.
Human serum
Maternal serum and serum from the umbilical cord were 
obtained from healthy pregnant women undergoing elective 
cesarean delivery at term (37-40 weeks’ gestational age; as de-
termined by ultrasound measurement of crown rump length) 
at the Birmingham Women’s Hospital, Birmingham Women’s 
& Children’s Hospital Foundation Trust. All participating 
women provided written informed consent prior to tissue 
collection (13/WM/0178 [2013]). In addition, we analyzed 
serum samples from patients with congenital adrenal hyper-
plasia due to 21-hydroxylase deficiency and patients with 
adrenocortical carcinoma in situ, selected for high-circulating 
11-oxygenated androgen concentrations and recruited 
from the Adrenal Clinic at the Queen Elizabeth Hospital 
Birmingham; patients had provided written informed consent 
prior to serum collection (University of Birmingham Human 
Biomaterials Resource Centre ethics application approved by 
North West 5 Research Ethics Committee, Haydock Park; 
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Steroid extraction and derivatization
Steroids were extracted from in vitro samples using me-
thyl tert-butyl ether (MTBE) as previously described (13, 
14). D2-T (1.5 ng), D7-11OHA4 (15 ng), and BPA (15 ng) 
were used as internal standards. MTBE was replaced with 
ethyl acetate (2.5 mL) for the extraction of estrogens from 
500-µL serum. Estrogens were derivatized using dansyl 
chloride (15-17).
Steroid analysis by ultra-high performance liquid 
chromatography tandem mass spectrometry 
Steroids were separated and quantified using an 
ACQUITY UHPLC (Waters Corp) coupled to a Xevo-
QTS triple quadrupole mass spectrometer (Waters Corp). 
Chromatographic separation was achieved using a BEH 
C18 (2.1  mm × 50  mm; 1.7  µM) column (Waters Corp) 
at 60 °C. The mobile phases consisted of 1% formic acid 
(solvent A) and 1% formic acid in methanol (solvent B) 
at a constant flow rate of 0.6  mL/min. Separation was 
achieved using an initial isocratic period (0.5 minutes) at 
40% B; a 1.5-minute linear gradient from 40% B to 60% 
B; a 0.5-minute linear gradient from 60% B to 75% B; and 
a 1.5-minute linear gradient from 75% B to 85% B. The in-
jection volume was 5 µL. Steroids were detected and quanti-
fied using multiple reaction monitoring (MRM) in positive 
electrospray ionization mode as shown in Table 1. In the 
absence of commercial standards, CypExpress (aromatase) 
was used to biosynthesize 11β-hydroxyestrone (11OHE1), 
11-ketoestrone (11KE1), and 11-keto-17β-estradiol 
(11KE2) from 11OHA4, 11KA4, and 11KT, respectively. 
We are confident of the correct identification of 11-oxy-
genated estrogens from their 11-oxygenated androgen pre-
cursors because: (1) all biosynthesis was inhibited by the 
aromatase-specific inhibitor, letrozole; (2) dansyl chloride, 
an estrogen-specific derivatization agent, was used to suc-
cessfully derivatize the products; and (3) the masses of the 
dansyl chloride–derivatized products correspond to the 
predicted 11-oxygenated estrogen masses when derivatized 
by dansyl chloride. The mass spectrometer instrumental 
parameters were as follows: source temperature, 150 °C; 
desolvation temperature, 350  °C; desolvation gas flow, 
800 L/hour; capillary voltage, 3.7 kV; cone voltage, 30 V; 
collision energy, 15 to 45 electron volt (eV); cone gas flow, 
150 L/hour; and collision gas flow, 0.15 mL/minute.
Whole-cell binding assay
Competitive whole-cell binding assays were performed in 
the COS-1 cell line as previously described (18). Ki ± SEM 
values for 11β-hydroxy-17β-estradiol (11OHE2) were 
determined from heterologous displacement curves using 
the median effective concentration (EC50) value, the pub-
lished Kd values for E2 (18), and the concentration of 
radiolabeled E2, according to the equation by Cheng and 
Prusoff (19).
Luciferase-reporter assays
Luciferase-reporter assays for estrogen receptor  α (ERα) 
and ERβ were performed in HEK293 cells as previously 
described (18).
Real-time proliferation assay
Real-time proliferation assays were carried out using an 
xCELLigence instrument (ACEA Biosciences). MCF7-
BUS cells were maintained in phenol red-free DMEM 
supplemented with 5% charcoal-stripped FBS and 1% 
penicillin-streptomycin (starvation medium) for 1 week 
before the proliferation assay. At the start of the assay, 
50-µL starved medium was added to each well of an 
E-plate 16 (ACEA Biosciences) and left to equilibrate for 
30 minutes before taking a background reading. During 
this time a suspension of the MCF7-BUS cells (100 000 
cells/mL) was prepared in starvation medium. A total of 
100 µL of the cell suspension was then added to each well 
and the plate was equilibrated for a further 30 minutes 
prior to initializing the run on the xCELLigence instru-
ment. Each run consisted of 400 sweeps with a 30-minute 
time interval. After 24 hours, 50 µL of unsupplemented 
phenol red-free DMEM containing 1  nM steroid (E2 or 
11OHE2) was added to each well and proliferation moni-
tored over 140 hours.
BrdU-based cell proliferation assay
MCF7arom cells were starved with phenol red-free and 
serum-free medium for 24 hours before treatment with the 
indicated androgen and drug treatments. Cell growth was 
subsequently measured using the BrdU cell proliferation 
assay (Roche Diagnostics). Anti-BrdU–peroxidase immune 
complexes were detected by substrate reaction and quan-
tified in an enzyme-linked immunosorbent assay reader at 
370 nm.
Analysis of relative gene expression by 
quantitative polymerase chain reaction
RNA extraction and complementary DNA synthesis 
were performed with TriReagent (Sigma-Aldrich) and the 
GoScript Reverse Transcription System kit (Promega). 
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using the KAPA SYBR FAST qPCR Master Mix for 
LightCycler with a LightCycler96 rapid thermal cycler 
instrument (Roche Life Science). Primer sequences were 
as follows: estrogen-responsive pS2 gene (pS2) for-
ward 5′-ATACCATCGACGTCCCTCCA-3′, pS2 reverse 
5′-AAGCGTGTCTGAGGTGTCCG-3′, cathepsin D 
(CTSD) forward 5′-GCGAGTACATGATCCCCTGT-3′, 
CTSD reverse 5′-CTCTGGGGACAGCTTGTAGC-3′, 
progesterone receptor (PR) forward 
5′-CTTAATCAACTAGGCGAGAG-3′, PR reverse 
5′-AAGCTCATCCAAGAATACTG-3′ glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) forward 
5′-TGAACGGGAAGCTCACTGG-3′, GAPDH reverse 
5′-TCCACCACCCTGTTGCTGTA-3′. Transcript levels 
were calculated relative to GAPDH transcript levels using 
the method described by Pfaffl (20).
Statistical analysis
All statistical analyses were performed in GraphPad Prism 
(version 9). Paired t tests (2-tailed) were used to compare 
Log Kd/Ki values of E2 and 11OHE2 for ERα and ERβ. 
Unpaired t  tests (2-tailed) were used to compare the sub-
strate utilization of each steroid to its substrate-specific 
control. For all other experiments statistical significance 
was determined by comparing each treatment to the vehicle 
control using a one-way analysis of variance and Dunnett’s 
multiple comparisons test.
Results
11-oxygenated androgens are aromatizable 
in vitro
Using a combination of in vitro and ex vivo test sys-
tems, and employing liquid chromatography–tandem 
mass spectrometry (LC-MS/MS) for steroid analysis, we 
tested whether 11-oxygenated androgens are substrates 
for human aromatase. The in vitro assays comprised 3 
cell-based test systems expressing aromatase: a reconsti-
tuted lysate from yeast overexpressing human aromatase 
(CypExpress); an MCF7 human breast cancer cell line en-
gineered to overexpress aromatase (MCF7arom) (12); and 
a human placental cell line, which endogenously expresses 
aromatase (JEG3). In all 3 aromatase-expression systems, 
11-oxygenated estrogens were detected after incubations 
with 11OHA4, 11KA4, and 11KT (Fig. 1A). These included 
11OHE1, 11OHE2, 11KE1, and 11KE2. We did not detect 
11-oxygenated estrogens after incubation with 11OHT. 
The addition of the specific aromatase inhibitor, letrozole, 
abolished all observed conversions (Fig.  1A). Analysis of 
substrate utilization revealed that 11-oxygenated andro-
gens were not all aromatized to the same extent, with sig-
nificant conversion for 11KA4 observed in all 3 cell-based 
test systems and for 11KT and 11OHA4 in 2 of the 3 sys-
tems, CypExpress and MCF7arom cells (Fig. 1B). Substrate 
utilization was abolished by the addition of letrozole, 
thereby suggesting that the substrates were converted by 
Table 1. Multiple reaction monitoring parameters for steroid analysis
Steroid metabolite RT, min Molecular  
ion, m/z
CV, V Quantifier  
ion, m/z
CE, eV Qualifier  
ion, m/z
CE, eV
A4 2.02 287.2 30 96.9 15 108.8 15
T 2.19 289.2 30 97.2 22 109 22
11OHA4 1.50 303.2 30 267.2 15 121 30
11KA4 1.22 301.2 35 257 25 265.2 25
11OHT 1.64 305.2 35 269 15 121 20
11KT 1.38 303.2 30 121 20 267 18
E1 3.53 504 20 171 35 156 45
E2 3.62 506 35 171 35 156 40
11OHE1 3.00 520.2 15 171 35 170 35
11KE1 2.98 518.2 15 171 35 170 35
11OHE2 3.16 522.2 15 171 35 504.2 20
11KE2 3.06 520.2 15 171 35 170 35
D2-T 2.19 291 30 99.1 20 111.2 30
D7-11OHA4 1.49 310.2 25 147.2 25 99.8 30
BPA 4.40 695 50 171 35 170 35
Retention time, molecular ion species, MRM mass transitions, CV, and CE for each steroid are reported. Internal standards: D2-T, D7-11OHA4, and BPA.
Abbreviations: 11KA4, 11-ketoandrostenedione; 11KE1, 11-ketoestrone; 11KE2, 11-keto-17β-estradiol; 11KT, 11-ketotestosterone; 11OHA4, 
11β-hydroxyandrostenedione; 11OHE1, 11β-hydroxyestrone; 11OHE2, 11β-hydroxy-17β-estradiol; 11OHT, 11β-hydroxytestosterone; A4, androstenedione; 
BPA, bisphenol A; CE, collision energy; CV, cone voltage; D2-T, testosterone 1,2-D2; D7-11OHA4, 11β-hydroxyandrostenedione 2,2,4,6,6,16,16-D7; E1, estrone; 
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Figure 1. Biosynthesis of 11-oxygenated estrogens from 11-oxygenated and classic androgens. A, Biosynthesis of 11-oxygenated estrogens by 3 in 
vitro aromatase expression systems. Assays (n = 3) were performed using 1-µM androgen substrate with and without 10-µM letrozole. Owing to 
the lack of commercially available 11-oxygenated estrogen standards, conversion data are expressed as the mean normalized responses (NR) from 
independent experiments each performed in triplicate (NR: [peak area/peak area of the internal standard]/protein). B, Percentage conversion of 
aromatase substrates as calculated substrate utilization. Data points are shown as mean ± SEM from 3 independent experiments each performed in 
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aromatase only (see Fig. 1B). All 3 cell-based systems cata-
lyzed the aromatization of the classic aromatase substrates, 
A4 and T (see Fig. 1B), though conversion was markedly 
lower in JEG3 cells, which had lower aromatase activity 
than the MCF7arom cells (Fig. 1C).
Next, we analyzed the aromatase-mediated biosynthesis 
of 11-oxygenated estrogens using explants obtained from 
fresh human placenta. In this ex vivo assay, LC-MS/MS de-
tected 11-oxygenated estrogens after incubation with each 
of the 4 11-oxygenated androgens (Fig. 1D).
Aromatase has 11β-hydroxylase activity toward 
classic estrogens
When we used the classic aromatase substrates, A4 and T, 
we observed the production of 11-oxygenated estrogens in 
all in vitro aromatase test systems and in human placenta 
explants (Fig.  1A and 1D), suggesting that aromatase it-
self might exert 11β-hydroxylase activity. Incubations of 
the CypExpress aromatase expression system with T (see 
Fig. 1A), E2 (Fig. 1E), or E1 (data not shown) yielded the 
11-oxygenated estrogen, 11OHE1; these conversions were 
abolished by the addition of letrozole. Contamination with 
an 11β-hydroxylase can be eliminated as neither A4 nor 
T was converted to 11OHA4 or 11OHT, as would have 
been expected in the presence of CYP11B1 or CYP11B2. 
Moreover, incubations of the human 11β-hydroxylase 
enzymes CYP11B1 or CYP11B2 with E2 or E1 failed to 
yield 11-oxygenated estrogens (data not shown). This is in 
agreement with a previous study that failed to detect the 
11β-hydroxylation of E1 by human adrenal slices (21).
11-oxygenated estrogens are bona fide estrogens
After confirming the biosynthesis of 11-oxygenated 
estrogens by human aromatase in  vitro and ex vivo, we 
next set out to determine their estrogenic activity. First, 
we confirmed that 11OHE2, the only commercially avail-
able 11-oxygenated estrogen, binds to both subtypes 
of the nuclear human ER, ERα and ERβ. The dissoci-
ation equilibrium constants (Ki) were 0.64 and 26.9  nM 
for ERα and ERβ, respectively (Fig.  2A). Next, using a 
promoter-reporter system, we showed that 11OHE2 could 
transactivate via both ERα and ERβ to a similar degree 
(not significantly different) to E2 (Fig.  2B). Cells trans-
fected only with the reporter showed no response (data not 
shown), thereby confirming activity via ERα or ERβ. These 
results were confirmed by demonstrating that the 11OHE2-
induced expression of endogenous estrogen-responsive 
genes in cells expressing both ER subtypes was abolished 
by ICI, a selective ER downregulator (Fig. 2C) (22). The 
estrogenic properties of 11OHE2 were further confirmed 
by demonstrating that 11OHE2, like E2, induced significant 
cell growth (P = .003) in the estrogen-responsive MCF7-
BUS breast cancer cell line (Fig. 2D). Our findings are in 
agreement with a previous study that showed that 11OHE2 
can bind to the ER and induce proliferation in estrogen-
responsive MCF-7 breast cancer cells (23).
Aromatization of 11-ketotestosterone yields an 
estrogenic response
Next, we determined whether the aromatization of the 
potent androgen 11KT could result in ER-mediated ef-
fects. We found that the aromatization of 11KT yielded 
the bioactive 11-oxygenated estrogen 11KE2 (see Fig. 1A 
and 1D), which induced cell growth (Fig. 3A) and an in-
crease in estrogen-dependent gene expression (Fig. 3B) in 
MCF7arom cells. These effects were abolished by the add-
ition of either letrozole or ICI, thereby confirming that 
11KT-mediated estrogen responses require both functional 
aromatase and ER (Fig. 3). As anticipated, 11OHT, which 
we demonstrated not to be aromatizable (see Fig.  1A), 
failed to yield an estrogenic response (Fig. 3C and 3D).
11-oxygenated estrogens are not detectable in 
circulation
Finally, after demonstrating that 11-oxygenated androgens 
are aromatizable in vitro and ex vivo, we used LC-MS/MS 
to screen for the presence of 11-oxygenated estrogens in 
human serum. We collected maternal serum and umbil-
ical cord blood at birth in 6 normal pregnancies, chosen 
because of the high levels of aromatase expressed during 
pregnancy. In addition, we analyzed serum from 10 patients 
with increased circulating 11-oxygenated androgen con-
centrations due to congenital adrenal hyperplasia, that is, 
increased substrate availability for 11-oxygenated estrogen 
activity in MCF7 (wild type), JEG3, and MCF7arom cells was determined using a tritiated water-release assay using A4 (1β-3H[N]) as substrate. Data 
represent 3 independent experiments shown as mean ± SEM. ***P less than .001; one-way analysis of variance and Dunnett’s multiple compari-
sons test. D, Biosynthesis of 11-oxygenated estrogens by human placenta explants (n = 6). E, Representative (multiple reaction monitoring [MRM]) 
chromatograms demonstrating the aromatase-catalyzed conversion of 1-µM E2 directly to 11OHE1 in the CypExpress system (n = 3). Conversion 
was inhibited by the addition of 10-µM letrozole. F, Schematic overview of 11-oxygenated estrogen biosynthesis. Androgens and estrogens are 
shown in blue and pink, respectively. All observed aromatase catalyzed reactions are shown in red. Steroids: 11OHA4, 11β-hydroxyandrostenedione; 
11KA4, 11-ketoandrostenedione; 11OHT, 11β-hydroxytestosterone; 11KT, 11-ketotestosterone; 11OHE1, 11β-hydroxyestrone; 11OHE2, 11β-hydroxy-17β-
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biosynthesis. We also analyzed serum samples from 7 pa-
tients with steroidogenically active adrenocortical car-
cinoma and increased 11-oxygenated adrenal androgen 
excretion, that is, increased substrate availability and po-
tentially dysregulated steroidogenesis due to ectopic ad-
renal aromatase expression. In all samples we detected 
classic estrogens, but no 11-oxygenated estrogens (data not 
shown). Our limit of detection for 11OHE2, the only com-
mercially available 11-oxygenated estrogen, was 20 pM 
and concentrations lower than this could therefore have 
gone undetected. Limits of detection could not be deter-
mined for the other 11-oxygenated estrogens because of a 
lack of standards.
Discussion
Despite being overlooked for several decades, it is now 
clear that 11-oxygenated androgens make a substantial 
contribution to the circulating androgen pool, particu-
larly in women (1-5). Because androgens are the obliga-
tory precursors to estrogen biosynthesis, it is essential to 
consider if 11-oxygenated androgens are aromatizable or 
if they serve as nonaromatizable androgens. This is the 
first study to describe the aromatization of 11-oxygen-
ated androgens in vitro. We show that 11KA4, 11OHA4, 
and 11KT are all aromatizable, albeit to a lower degree 
than the classic aromatase substrates. 11OHT was the 
only nonaromatizable 11-oxygenated androgen in the 
3 cell-based aromatase expression systems employed in 
this study. The detection of 11-oxygenated estrogens in 
the human placenta explant culture incubations with 
11OHT can be explained by the prevalent expression of 
HSD11B2 and HSD17B2 in placental tissue (24). These 
enzymes can convert 11OHT to 11KT and 11OHA4, re-
spectively (1) (Fig. 1F), which both were aromatized in 
all in vitro and ex vivo systems we employed. Similarly, 
the accumulation of 11KE2 as the primary 11-oxygen-
ated estrogen product in the placenta explant cultures is 
explained by the high expression of HSD11B2 and the 
estrogen-converting enzyme HSD17B1 in human pla-
centa (24) (Fig. 1F).
Our data also revealed that aromatase can catalyze the 
11β-hydroxylation of estrogens resulting from the aroma-
tization of A4 and T.  This activity has likely previously 
gone undetected because of the longstanding use of triti-
ated water-release assays for aromatase activity that do 
Figure 2. 11-Oxygenated estrogens bind and activate the human es-
trogen receptors α and β. A, Binding affinities of 11β-hydroxy-17β-
estradiol (11OHE2) relative to 17β-estradiol (E2) as determined by 
whole-cell binding assays (n = 3). Binding data were analyzed with 
nonlinear regression assuming competitive binding to one class of 
binding sites, and the Ki ± SEM values for 11OHE2 determined from 
a heterologous displacement curve. B, Transactivation of human es-
trogen receptor α (Erα) and ERβ by 11OHE2 and E2 (n = 3). *P less than 
.05; **P less than .005; one-way analysis of variance (ANOVA) and 
Dunnett’s multiple comparisons test, compared to the vehicle control 
set as 1. C, Induction of ER-regulated gene expression (pS2, estrogen-
responsive pS2 gene; CTSD, cathepsin D; PR, progesterone receptor) 
in MCF7-BUS cells by 1-nM 11OHE2 and E2 in the absence and presence 
of 1-µM fulvestrant (ICI). *P less than .05; **P less than .005; and ***P 
less than .001; one-way ANOVA and Dunnett’s multiple comparisons 
test, compared to the vehicle control set as 1. D, Real-time proliferation 
of MCF7-BUS cells as induced by 1-nM 11OHE2 and E2 (n = 3). All results 
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not directly identify the measured estrogen products (25-
27). Dual aromatase and 11β-hydroxylase activity cata-
lyzed by a single enzyme is supported by the observation 
that CYP11B has a secondary aromatase function (28, 
29). Incubations of aromatase with either T or E2 yielded 
primarily 11OHE1 and not 11OHE2 as one would antici-
pate, suggesting additional 17β-hydroxysteroid dehydro-
genase activity (Fig. 1E and 1F), which warrants further 
investigation in the future. Incubations of the human 
11β-hydroxylase enzymes CYP11B1 or CYP11B2 with 
E2 or E1 failed to yield 11-oxygenated estrogens (data 
not shown), demonstrating that although these enzymes 
are essential for the biosynthesis of 11-oxygenated andro-
gens (30, 31), they play no direct role in the production of 
11-oxygenated estrogens. In agreement with our findings, 
a previous study had shown that incubations of human ad-
renal slices, the exclusive site of CYP11B1 and CYP11B2 
expression, failed to yield 11β-hydroxylated products 
when using E1 as a substrate (21).
In terms of activity, we show that 11OHE2, the only 
commercially available 11-oxygenated estrogen, binds 
and activates ERα and ERβ in a similar manner to E2. 
11OHE2 also stimulated proliferation and expression of 
estrogen-responsive genes in an estrogen-responsive breast 
cancer cell line, thereby confirming its estrogenic activity. 
Moreover, aromatization of the potent 11-oxygenated an-
drogen, 11KT, to 11KE2 in MCF7arom cells (see Fig. 1A) 
induced cell growth (Fig. 3A) and an increase in estrogen-
dependent gene expression (Fig.  3B), thereby indirectly 
demonstrating the 11KE2 is also a bona fide estrogen. 
The relative estrogenic activity of 11OHE2 and 11KE2 
can be determined only when 11KE2 becomes commer-
cially available or is custom synthesized. This comparison 
will be of interest given that 11KT is a more efficacious 
Figure 3. Aromatization of 11-ketotestosterone (11KT) elicits an estrogen response. A, 11KT-mediated estrogen-dependent proliferation (100 nM) 
as measured by a BrdU proliferation assay is inhibited by 1-µM letrozole or fulvestrant in MCF7arom cells (n = 3). **P less than .005; one-way ana-
lysis of variance (ANOVA) and Dunnett’s multiple comparisons test, compared to the control set as 100%. B, 11KT-mediated (100 nM) increase in 
estrogen-dependent gene expression (cathepsin D [CTSD] and progesterone receptor [PR]) is inhibited by 1-µM letrozole or fulvestrant in MCF7arom 
cells (n = 3). **P less than .005 and ***P less than .001; one-way ANOVA and Dunnett’s multiple comparisons test, compared to the vehicle control 
set as 1. C, 11KT, but not 11-hydroxytestosterone (11OHT), induce estrogen-dependent proliferation in MCF7arom as measured by a BrdU prolifer-
ation assay. *P less than .05 and **P less than .005; one-way ANOVA and Dunnett’s multiple comparisons test, compared to control set as 100%. D, 
Schematic illustrating the aromatase and ER-dependent estrogen response elicited by 11KT, but not 11OHT. Experiments A, B, and C are represented 
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androgen than 11OHT (1). It also remains to be deter-
mined whether 11OHE1 and 11KE1 are estrogenic. Our re-
sults differ from one previous study conducted in wild-type 
MCF7 cells that concluded that 11KT is not aromatizable 
(23). However, this is likely explained by the much lower 
aromatase activity in wild-type MCF7 cells as compared to 
the aromatase-overexpressing MCF7arom cell line we used 
for our experiments (see Fig. 1C).
Indeed, the degree of aromatization observed was de-
pendent on the level of aromatase expression and activity 
in our in vitro test systems, with only 11KA4 being sig-
nificantly aromatized in JEG3 cells, which had the lowest 
aromatase activity (Fig. 1B and 1C). Even in MCF7arom 
cells, only 46% of 11KA4, the best 11-oxygenated an-
drogen substrate, was aromatized, whereas 100% of A4 
was converted to E1. The comparatively poor aromatiza-
tion of 11-oxygenated androgens was further highlighted 
by the inability to detect 11-oxygenated estrogens in serum 
samples representative of high aromatase expression (preg-
nancy and cord serum) or high substrate levels (congenital 
adrenal hyperplasia or adrenocortical carcinoma with ele-
vated 11-oxygenated androgen levels). These findings sug-
gest that while 11-oxygenated androgens are aromatizable 
in vitro and even ex vivo, aromatization may be limited 
in vivo because of the relatively low activity of aromatase 
toward 11-oxygenated androgens in comparison to the 
classic substrates. The 11-oxygenated androgens may 
therefore serve almost exclusively as androgens in vivo and 
not also as estrogen precursors. However, the intracrine 
biosynthesis of 11-oxygenated estrogens within aromatase-
expressing peripheral target cells cannot be ruled out. Once 
standards for the 11-oxygenated estrogens become avail-
able, this will allow for the more comprehensive quantifi-
cation of these estrogens in serum and tissue. Interestingly, 
using paper chromatography, and chemical and infrared 
analyses, 11OHE1 was previously reported to be a major 
product of a feminizing adrenal carcinoma (32), suggesting 
that in vivo biosynthesis of 11-oxygenated estrogens does 
occur under certain circumstances.
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